A Phase 3, Multi-Site, Open-Label Study of the Long Term Safety and Tolerability of 2 Oral Doses of CP-690,550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis
|Effective start/end date
|1/7/11 → 6/30/16
- PFIZER, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.